Live Biotherapeutics Drug Discovery Services for Atherosclerosis
Current therapies against atherosclerosis, which mostly target dyslipidemia associated with the disease, have a considerable residual risk together with various side effects. Probiotics have the potential to be used as a cheap, non-invasive, and with little side effects way to reduce atherosclerosis and have brought worldwide benefits. Creative Biolabs is passionate about next-generation probiotics (NGPs) discovery, offering comprehensive services across every stage of NGPs development. We're known for our deeply rooted expertise, with a global team dedicated to bringing innovations to the market.
About Atherosclerosis
Atherosclerosis, the underlying cause of cardiovascular diseases such as myocardial infarction, cerebrovascular accident, and peripheral vascular disease, is the leading cause of global mortality. Dysbiosis in the gut compromises the intestinal barrier function leading to the leakage of lipopolysaccharide (LPS) and other bacterial components (e.g., peptidoglycans) into the circulation, triggering an inflammatory response that drives atherosclerosis.
Treatment of Atherosclerosis
Probiotics improve gut barrier function via the strengthening of the epithelial tight junctions. By reducing gut leakage, probiotic bacteria strengthen immunological and non-immunological gut barrier function and reduce the translocation of microbial immunogens. Probiotic supplementation (especially Lactobacillus spp.) has been shown to beneficially modify some major atherosclerosis-associated cardiovascular risk factors, including hypercholesterolemia, dyslipidemia, hypertension, and chronic inflammation.
-
Lactobacillus Plantarum (L. Plantarum) was able to reduce several cardiovascular disease risk factors in smokers including positive metabolic changes, decrease in levels of proinflammatory cytokine IL-6, and reduced adhesion of monocytes to endothelial cells.
-
Eight-week-old mice were fed a Western diet with or without Lactobacillus acidophilus (L. acidophilus) daily for 16 weeks. L. acidophilus protected mice from atherosclerosis by reducing their plasma cholesterol by 40%.
-
Fecal lactobacillus and bifidobacterium counts were significantly higher in the Lactobacillus (L. acidophilus) treatment groups than in the control groups. L. acidophilus was detected in the rat small intestine, colon, and feces during the feeding trial. The bacterial levels remained high even after the administration of lactic acid bacteria had been stopped for 2 weeks. These suggest that administration of L. acidophilus can protect against atherosclerosis through the inhibition of intestinal cholesterol absorption.
Safety of Probiotics
To investigate whether L. acidophilus treatment had any impact on the morphology of the small intestine, we stained intestinal sections with hematoxylin and eosin. L. acidophilus did not influence the morphology of the small intestine. All specimens had intact villi, epithelia, enterocytes, and brush borders. Therefore, L. acidophilus treatment does not affect gross small intestinal morphology.
Highlights of Our Probiotic Drug Discovery Services
Atherosclerosis is ranked among the most serious health problems in human medicine. Probiotics could be effectively used in the prevention of atherosclerosis and decrease disease risk. Creative Biolabs can provide flexible probiotics solutions for your choice, either stand-alone service or integrated project is both welcome to meet every specific demand.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
